PURE EP(tm) System evaluation is being conducted under the leadership of
“We are very pleased to commence our clinical operations at
To date, more than 450 patient cases have been conducted with the PURE EP(tm) System by over 30 physicians across seven clinical sites.
About
The Company’s first product, PURE EP (tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the
Attachment
- PURE EP
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations54 Wilton Road , 2nd floorWestport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
PURE EP
![](https://ml.globenewswire.com/media/acdd6a50-5d6f-4e41-aca7-f866d678fb91/medium/pure-ep.png)
Pure EP(tm) System
2021 GlobeNewswire, Inc., source